Lung Metastates | Nano Publications

2020 – ASTRO – NBTXR3 in Combination with Anti-PD-1

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Immune checkpoint inhibitors (ICIs) are being increasingly used to improve patient outcomes across different cancer types. However, the response rate to ICIs remains low (~15%), indicating the need for novel strategies to improve treatment outcome. Emerging evidence suggests that radiation therapy (RT) could potentially enhance the antitumor response and provide synergy with ICIs. RT dose and ultimate efficacy are however limited by toxicity related to exposure of healthy tissues. […]

Continuer la lecture…

2020 – ASCO – NBTXR3 With Anti PD1 Therapy

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Despite the past decade of transformative advances in immuno-oncology, the response rate to checkpoint inhibitors (ICIs) remains low (~15%). There is significant interest in developing strategies to overcome resistance to these treatments, thus increasing response rate. Emerging evidence suggests that radiation therapy (RT) could potentially augment the antitumor response to ICIs through synergic effect. […]

Continuer la lecture…